Abstract:Abstract Mycosis fungoides (MF), the most common subtype of primary cutaneous T-cell lymphoma, is characterized by the proliferation of skin-homing, malignant CD4+ T cells. In early-stage disease (IA–IIA) patients develop cutaneous patches and plaques; late-stage disease (IIB–IVB) is characterized by tumours, erythroderma, and blood and/or lymph-node involvement. Effective skin-directed treatment options for all stages of disease are limited. Topical chlormethine gel (Ledaga), known as nitrogen mustard, is an antineoplastic alkylating agent, licensed in England in August 2021 for the treatment of MF in patients who have received prior skin-directed therapy (Lessin SR, Duvic M, Guitart J et al. Topical chemotherapy in cutaneous T-cell lymphoma: positive results of a randomized, controlled, multicentre trial testing the efficacy and safety of a novel mechlorethamine, 0.02%, gel in mycosis fungoides. JAMA Dermatol 2013; 149: 25–32). The aim of this study was to evaluate our experience of using chlormethine gel in a single UK centre and to offer practical guidance in its use. All patients who commenced topical chlormethine gel in our unit between January 2022 (when chlormethine gel was first available to us) and December 2023 were identified. An intention-to-treat, retrospective analysis of medical records was performed. In total, 66 patients (58% male sex) were identified with a mean age at the start of treatment of 60.3 years (SD 14.6). Multiple stages of MF (IA 35%, IB 47%, IIB 9%, III 2%, IVA1 2%, IVA2 6%) were represented. Prior to commencing chlormethine gel, all patients had used topical steroids; 17% had received no other prior treatment. Overall, 18% were receiving concomitant systemic therapy, phototherapy or radiotherapy for their MF during chlormethine treatment. The mean duration of treatment with chlormethine gel was 264 days; 64% of patients consider the treatment a success and continue ongoing episodic treatment or have stopped due to a complete or partial response. A total of 8% of patients stopped due to disease progression, 5% due to lack of response and 21% due to unacceptable side-effects. Overall, 82% of all patients experienced toxicities; these were exclusively cutaneous, most commonly erythema (32%) and pruritus (32%). Toxicities were largely managed with brief treatment breaks, reducing the frequency of chlormethine application, emollients and topical steroids, enabling patients to continue treatment. We present real-life data on the use of topical chlormethine gel in our cohort of patients with MF and demonstrate that it is an effective, well-tolerated skin-directed therapy. Skin toxicities can generally be managed conservatively.

Chlormethine Gel for Treatment of Patients with Mycosis Fungoides: Best Practices and Guidance to Clinicians

Chlormethine Gel for the Treatment of Skin Lesions in All Stages of Mycosis Fungoides Cutaneous T-Cell Lymphoma: A Narrative Review and International Experience

Chlormethine Gel for Patients with Mycosis Fungoides Cutaneous T Cell Lymphoma: A Review of Efficacy and Safety in Clinical Trial and Real-World Settings

Chlormethine gel in combination with other therapies for treatment of mycosis fungoides: a review with patient cases

Topical chlormethine gel in the treatment of mycosis fungoides: A single-center real-life experience and systematic review of the literature

Expert opinions and clinical experiences with chlormethine gel as maintenance treatment for patients with mycosis fungoides

Mechanism of action of chlormethine gel in mycosis fungoides

BI16 Real-life experience using topical nitrogen mustard gel in the treatment of stage IA–IVA2 mycosis fungoides: a single-centre experience of 66 patients

Chlormethine gel is effective for the treatment of skin lesions in patients with early- and late-stage mycosis fungoides in clinical practice

Chlormethine Gel is Efficient and Safe in Mycosis Fungoides Skin Lesions

Effectiveness and tolerability of chlormethine gel for the management of mycosis fungoides: a multicenter real-life evaluation

Response to Chlormethine/Mechlorethamine gel Maintenance Treatment Regimen in Patients With Mycosis Fungoides: A Single-center Retrospective Study

Chlormethine Gel Versus Chlormethine Ointment for Treatment of Patients with Mycosis Fungoides: A Post-Hoc Analysis of Clinical Trial Data

Maintenance and Concomitant Therapy Use with Chlormethine Gel Among Patients with Stage IA/IB Mycosis Fungoides-Type Cutaneous T-Cell Lymphoma (MF-CTCL): A Real-World Evidence Study

The PROVe Study: US Real-World Experience with Chlormethine/Mechlorethamine Gel in Combination with Other Therapies for Patients with Mycosis Fungoides Cutaneous T-Cell Lymphoma

Approach to Mycosis Fungoides in children (ARMFUL study): consensus-based recommendations

Skin-directed therapy and biologic response modifiers in mycosis fungoides

ASTCT and USCLC Clinical Practice Recommendations for Allogeneic Stem Cell Transplant in Mycosis Fungoides and Sézary Syndrome

Advances in the pharmacological management of cutaneous T-cell lymphoma

Multidisciplinary Approach to the Diagnosis and Therapy of Mycosis Fungoides

Application of the Current Diagnostic Algorithm for Early Mycosis Fungoides to a Single Center Cohort: Identification of Challenges and Suggestions for Modification.